Absci (ABSI) Tax Provisions (2021 - 2026)
Absci (ABSI) posted Tax Provisions of $18000.0 for Q1 2026, up 111.11% sequentially from -$162000.0 in Q4 2025, and up 550.0% YoY from $2769.2 in Q1 2025.
Absci (ABSI) Tax Provisions (2021 - 2026) Analysis & Trends
Absci has reported Tax Provisions for 6 years, with the latest figure at $18000.0 in Q1 2026.
- Quarterly Tax Provisions rose 550.0% year-over-year to $18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91000.0 (up 68.52% YoY) and the FY2025 annual result came in at $69000.0, down 1.43% from the prior year.
- Tax Provisions improved to $18000.0 in Q1 2026 per ABSI's latest filing, from -$162000.0 in the prior quarter.
- Over five years, Tax Provisions peaked at $621000.0 in Q1 2022 and troughed at -$500000.0 in Q4 2022.
- A 5-year average of -$12750.0 and a median of $15000.0 in 2024 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2025 and 2026: Tax Provisions plunged 871.43% in 2025, then jumped 550.0% in 2026.
- Over 5 years, Tax Provisions stood at -$500000.0 in 2022, then surged by 109.6% to $48000.0 in 2023, then tumbled by 56.25% to $21000.0 in 2024, then slumped by 871.43% to -$162000.0 in 2025, then jumped by 111.11% to $18000.0 in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered $18000.0, -$162000.0, and $104000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 40,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | -162,000.00 |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | 37,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Dec 31, 2023 | 48,000.00 |
| Sep 30, 2023 | 34,000.00 |
| Jun 30, 2023 | 11,000.00 |
| Mar 31, 2023 | 7,000.00 |
| Dec 31, 2022 | -500,000.00 |
| Sep 30, 2022 | -312,000.00 |
| Jun 30, 2022 | -270,000.00 |
| Mar 31, 2022 | 621,000.00 |
| Dec 31, 2021 | -1.10 Mn |
| Sep 30, 2021 | -1.70 Mn |
| Jun 30, 2021 | -5.60 Mn |